BeyondSpring (BeyondSpring) Institutional Ownership : 0.29% (As of May. 02, 2024)

View and export this data going back to 2017. Start your Free Trial

What is BeyondSpring Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BeyondSpring's institutional ownership is 0.29%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BeyondSpring's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BeyondSpring's Float Percentage Of Total Shares Outstanding is 60.93%.

BeyondSpring Institutional Ownership Historical Data

The historical data trend for BeyondSpring's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeyondSpring Institutional Ownership Chart

BeyondSpring Historical Data

The historical data trend for BeyondSpring can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	0.36	0.35	0.35	0.33	0.30	0.30	0.29	0.29	0.29	0.29

BeyondSpring Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

BeyondSpring (BeyondSpring) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeyondSpring Inc (NAS:BYSI) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

28 Liberty Street, 39th Floor, New York, NY, USA, 10005

Website

https://www.beyondspringpharma.com

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform. It has a scalable business model integrating clinical resources in the United States and China.